expand_moreexpand_less
Aeon
Al Jazeera
América Economía
Blitz
Buenos Aires Herald
Deutsche Welle
Dnevnik
E-International
Haaretz
Il Manifesto Global
Japan Today
Khaama PressMiddle East Monitor
New Eastern OutlookNikkei Asian ReviewOped Column
Pravda.sk
Project Syndicate
Psychology TodayRT.comSME.sk
South China Morning PostThe Asahi ShimbunThe Japan NewsThe Japan Times
The Korea TimesThe Times of IsraelThe Times of Israel (Blogs)
TRT WorldVečer
العين الإخبارية 
|
 |
Naomi KresgeFortune |
Patients on semaglutide were less than half as likely to overdose as those on insulin.
Positive results in the early stages of Roche's weight-loss pill development had given investors hope it could quickly catch up with rivals Novo...
Positive results in the earliest stages of development have driven about $93 billion in market value gains this year for obesity-drug makers.
login
who are we?
contact us
qosheapp
